J. Jean Cui, BlossomHill Therapeutics CEO
February 29, 2024 08:00 AM EST
Financing
Startups

Blos­somHill rais­es $100M in bid to re­peat founder­s' can­cer suc­cess at Turn­ing Point

Kyle LaHucik

Senior Reporter

Blos­somHill Ther­a­peu­tics has closed a $100 mil­lion Se­ries B to bring three of its on­col­o­gy small mol­e­cules in­to the clin­ic and col­lect ear­ly ef­fi­ca­cy da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times